ASND vs. NTRA: Ascendis Pharma vs. Natera Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while Ascendis Pharma (ASND) is defensive at 0.38 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.

Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Ascendis Pharma (ASND) reports 70.85%, ranking against industry peers normally.

Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Natera (NTRA) at 35.90% is closer to the peer norm — faster top-line expansion for ASND.

Neither Ascendis Pharma (ASND) nor Natera (NTRA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Ascendis Pharma (ASND) at 2.99 and Natera (NTRA) at 2.81 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Ascendis Pharma (ASND) at 0.31 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Ascendis Pharma (ASND) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: Ascendis Pharma (ASND) at 10.45 sits in the upper P/B ratio quartile, and Natera (NTRA) at 23.99 prices even higher, above its industry range.

Valuation Metrics